Clinical Trials Update: Sept. 19, 2006
Genital Herpes Ulcerative Colitis Restless Legs
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
Novartis Pharmaceuticals Corp. is conducting a clinical research study to evaluate one-day treatment with famciclovir compared with three-day treatment with valacyclovir in people with recurrent genital herpes. Volunteers 18 and older with a diagnosis of genital herpes who have had at least four outbreaks in the preceding 12 months and are willing to discontinue current herpes medication may be included. Patients will be excluded from the study if they are pregnant or breast feeding, have a history of renal dysfunction, or have a suppressed immune system.
The research sites are located across the United States.
This study will evaluate the safety and efficacy of intravenous visilizumab in people with intravenous steroid refractory ulcerative colitis. Candidates with a UC diagnosis by colonoscopy or barium enema within 36 months who have active disease despite ongoing treatment with steroids may qualify. Eligible patients will be randomly assigned to receive visilizumab (Nuvion) or placebo, and will participate in 90 days of intensive weekly-to-monthly evaluations.
The research sites are located worldwide.
If you have an unpleasant sensation in my legs that create the urge to move them, and symptoms get worse in the evening and at night, you may have restless legs syndrome. If you've had these symptoms for three months or longer and are at least 18, you may qualify for this study. Participants may receive all study-related exams and investigational medication at no cost.
The research site is in Santa Rosa, Calif.
Copyright 2006 Thomson CenterWatch. All rights reserved.